The impact of MMX mesalazine on disease‐specific health‐related quality of life in ulcerative colitis patients

Past studies with ulcerative colitis (UC) patients indicate that disease activity strongly predicts health‐related quality of life (HRQL).

[1]  M. Safdi,et al.  Strategies in maintenance for patients receiving long‐term therapy (SIMPLE): A study of MMX mesalamine for the long‐term maintenance of quiescent ulcerative colitis* , 2012, Inflammatory bowel diseases.

[2]  P. Rutgeerts,et al.  Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies , 2012, Inflammatory bowel diseases.

[3]  E. Kuipers,et al.  Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation , 2011, Inflammatory bowel diseases.

[4]  B. Sands,et al.  Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? , 2011, Inflammatory bowel diseases.

[5]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[6]  P. Fayers,et al.  How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses , 2009, Quality of Life Research.

[7]  J. Korzenik,et al.  Validation of interactive voice response system administration of the short inflammatory bowel disease questionnaire , 2008, Inflammatory bowel diseases.

[8]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[9]  P. Higgins,et al.  The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis , 2008, Alimentary pharmacology & therapeutics.

[10]  L. Lix,et al.  Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[11]  Jan E. Irvine.  Quality of life of patients with ulcerative colitis: Past, present, and future , 2008, Inflammatory bowel diseases.

[12]  S. Schreiber,et al.  Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis , 2008, Gut.

[13]  K. Nordin,et al.  Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. , 2008, Journal of psychosomatic research.

[14]  P. Rutgeerts,et al.  Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis , 2007, Inflammatory bowel diseases.

[15]  M. Kamm,et al.  MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials , 2007, Alimentary pharmacology & therapeutics.

[16]  P. Rutgeerts,et al.  The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients , 2007, The American Journal of Gastroenterology.

[17]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[18]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  W. Stremmel,et al.  Health‐related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis , 2006, Inflammatory bowel diseases.

[20]  A. Mokrowiecka,et al.  The comparison of Health-Related Quality of Life (HRQL) in patients with GERD, peptic ulcer disease and ulcerative colitis. , 2006, Advances in medical sciences.

[21]  F. Casellas,et al.  Impairment of Health‐Related Quality of Life in Patients With Inflammatory Bowel Disease: a Spanish Multicenter Study , 2005, Inflammatory bowel diseases.

[22]  A. Francavilla,et al.  A New Oral Delivery System for 5‐ASA: Preliminary Clinical Findings for MMX , 2005, Inflammatory bowel diseases.

[23]  Christoph Meisner,et al.  Determinants of Life Satisfaction in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[24]  M. Schwartz,et al.  Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis? , 2005, The American Journal of Gastroenterology.

[25]  Elaine McColl,et al.  Predictors of Quality of Life in Ulcerative Colitis.: The Importance of Symptoms and Illness Representations , 2005, Inflammatory bowel diseases.

[26]  S. Travis,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.

[27]  E. McColl,et al.  A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis , 2004, Quality of Life Research.

[28]  M. Vatn,et al.  Health‐related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis , 2004, Scandinavian journal of gastroenterology.

[29]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee , 2004, American Journal of Gastroenterology.

[30]  C. Seal,et al.  The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis , 2001, American Journal of Gastroenterology.

[31]  G. Järnerot,et al.  Validation of the inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis. , 2001, Scandinavian journal of gastroenterology.

[32]  J. Marshall,et al.  Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis , 2000, American Journal of Gastroenterology.

[33]  R. Thisted,et al.  A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis , 2000, American Journal of Gastroenterology.

[34]  M. Welfare,et al.  The SIBDQ: further validation in ulcerative colitis patients , 2000, American Journal of Gastroenterology.

[35]  E. Irvine,et al.  The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. , 1996, The American journal of gastroenterology.

[36]  T. Yao,et al.  An index of disease activity in patients with ulcerative colitis. , 1992, The American journal of gastroenterology.

[37]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[38]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.